Medication info
Sitagliptin Phosphate Hydrate 25 mg Tablet

Sitagliptin Phosphate Hydrate 25 mg Tablet

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Phosphate Hydrate›32.125mg / 1 tablet
Manufacturer / importer
Jongkundang Co., Ltd.
Appearance
Pink-colored round film-coated tablet
Packaging
PTP - 30 tablets/box [(10 tablets/PTP x 3)]
Approval status
Active

MFDS item code 201503507 · Approved 2015.05.29 · Insurance code 643307060

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
Whether used as monotherapy or in combination therapy, administer 100 mg once daily; the maximum daily dose is 100 mg. This medicine may be taken with or without food. When this medicine is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia caused by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). Patients with renal impairment Since dosage adjustment is required according to renal function, assessment of renal function is recommended before treatment with this medicine and periodically thereafter. 1. No dose adjustment is necessary in patients with mild renal impairment (estimated glomerular filtration rate [eGFR] ≥ 60mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dose adjustment is necessary in patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 45mL/min/1.73 m2 and < 60mL/min/1.73 m2). 3. In patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 30mL/min/1.73 m2 and < 45mL/min/1.73 m2), administer 50 mg once daily. 4. In patients with severe renal impairment (estimated glomerular filtration rate [eGFR] ≥ 15mL/min/1.73 m2 and < 30mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (estimated glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2), administer 25 mg once daily. This medicine may be administered regardless of the timing of dialysis.

Ingredients

Manufacturer
Jongkundang Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

  • Difficulty in blood sugar control in patients with type 2 diabetes
View approved original text

This medication is used in conjunction with diet and exercise to help control blood sugar in patients with type 2 diabetes. It can be used alone, but if blood sugar control is difficult, it may be administered in combination with metformin, sulfonylureas, thiazolidinediones, or insulin. In particular, if existing diabetes treatments do not provide sufficient effect, this medication can be added to enhance treatment efficacy. It helps improve blood sugar control when used with various medications. Overall, it is used to effectively improve blood sugar management in type 2 diabetes.

How to take

Adult dose

Whether used as monotherapy or in combination therapy, administer 100 mg once daily; the maximum daily dose is 100 mg. This medicine may be taken with or without food. When this medicine is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia caused by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). Patients with renal impairment Since dosage adjustment is required according to renal function, assessment of renal function is recommended before treatment with this medicine and periodically thereafter. 1. No dose adjustment is necessary in patients with mild renal impairment (estimated glomerular filtration rate [eGFR] ≥ 60mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dose adjustment is necessary in patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 45mL/min/1.73 m2 and < 60mL/min/1.73 m2). 3. In patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 30mL/min/1.73 m2 and < 45mL/min/1.73 m2), administer 50 mg once daily. 4. In patients with severe renal impairment (estimated glomerular filtration rate [eGFR] ≥ 15mL/min/1.73 m2 and < 30mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (estimated glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2), administer 25 mg once daily. This medicine may be administered regardless of the timing of dialysis.

Precautions

This medication can cause severe allergic reactions, so if symptoms such as rash, difficulty breathing, or swelling of the face or neck appear after taking the medication, you must immediately stop taking it and consult a doctor. In addition, acute pancreatitis, a serious inflammation of the pancreas, may occur; therefore, if abdominal pain, vomiting, or persistent discomfort in the abdomen occurs, quickly inform medical personnel. This medication should not be used in patients with type 1 diabetes or diabetic ketoacidosis, nor should it be taken by individuals with an allergy to the active ingredient. Patients with impaired renal function may have delayed excretion of this medication, so dosage adjustments should be made cautiously. During treatment, side effects such as cold symptoms, headaches, indigestion, and diarrhea may occur, and especially when taken with other blood sugar-lowering agents, hypoglycemia symptoms may occur more frequently. Hypoglycemia symptoms include dizziness, cold sweat, and severe fatigue, so caution is needed. This medication can also be used in the elderly, but regular kidney function tests should be conducted, and pregnant or breastfeeding women are advised not to take it. In case of overdose, general treatment should be conducted along with monitoring the heart condition, and if necessary, dialysis may be performed to remove the medication. Rare side effects such as joint pain or skin diseases may develop during long-term use, so inform a doctor if any unusual symptoms occur. Finally, there are minimal special interactions when used in combination with other medications, but it is important to consult medical personnel if taking specific medications.

Side effects

  • anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • hypoglycemia
  • nasopharyngitis
  • upper respiratory infection
  • headache
  • diarrhea
  • abdominal pain
Show 30 more
  • nausea
  • peripheral edema
  • constipation
  • vomiting
  • severe and disabling arthralgia
  • vesicular pemphigoid
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • rhabdomyolysis
  • elevated liver enzymes
  • acute renal failure
  • pneumonia
  • diabetes complications
  • metabolic acidosis
  • falls
  • cardiac arrest
  • dyspepsia
  • dizziness
  • elevated triglycerides in the blood
  • gastritis
  • increased low-density lipoprotein
  • hyperglycemia
  • weight loss
  • hypertension
  • hypernatremia
  • erectile dysfunction

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to prevent air or moisture from entering, and it is best to store it at room temperature between 1 and 30 degrees Celsius. By doing so, the effectiveness of the medication can be maintained and deterioration can be prevented.

Appearance and packaging

Appearance

Pink-colored round film-coated tablet

Package unit

PTP - 30 tablets/box [(10 tablets/PTP x 3)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.